source
- Biotech earnings season kicks off as Agios reports Phase 2 setback for sickle-cell drugThe second‑quarter earnings window has begun, and analysts are zeroing in on a handful of biotech companies with high‑profile catalysts. Smaller biotechs are increasingly opting to launch their pr…
- Teva says it has time to prepare for upcoming US tariffs on imported generic drugsTeva CEO Richard Francis said the company believes it has sufficient time to prepare for the tariffs the Trump administration is considering on generic drugs imported from outside the United States…